DIRS.INFO The most relevant business & tech news

☆ Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
▼ + stars: | 2024-10-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business. But Merck's vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., posted another quarter of lighter-than-expected sales. Revenue from the shot, Gardasil, fell 11% compared to the year-earlier period, mainly due to lower demand in China. The company booked $16.66 billion in revenue for the third quarter, up 4% from the same period a year ago. The loss of exclusive rights to the medicine will likely cause sales to fall, forcing the company to draw revenue from elsewhere.

Persons: Keytruda, Curon, Merck Organizations: Merck, LSEG Locations: Rahway , New Jersey, U.S, China

☆ These dividend-paying stocks could be in the 'early innings' of a rally
▼ + stars: | 2024-10-18 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

"As evidenced by XLV [Health Care Select Sector SPDR Fund], price is back through the 50 day [moving average] on this relief rally," he said. "Not yet overbought, it looks to us like the early innings of a reacceleration back towards the highs. XLV YTD mountain Health Care Select Sector SPDR Fund year to date On top of that rally is the added benefit of dividend payouts on many health care stocks. At least 51% of the Wall Street analysts who cover each stock rates it a buy, according to FactSet data. CI YTD mountain Cigna year to date Cigna beat earnings and revenue estimates in its second quarter when it reported results in August.

Persons: Rob Ginsberg, Abbott, Robert Ford, Dickinson, Cigna, Lina Khan, Merck Organizations: Wolfe Research, SPDR, CNBC Pro, Wall Street, nab, Abbott Laboratories, Company, Cigna's, Federal Trade Commission, CVS Health, UnitedHealth, Merck, Co Locations: . Connecticut

☆ Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda
▼ + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Merck on Tuesday reported second-quarter revenue and adjusted earnings that topped Wall Street's expectations as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and vaccines portfolios and a newly launched cardiovascular drug. The pharmaceutical giant also raised its full-year sales forecast to a range of $63.4 billion to $64.4 billion on increased demand for key products, particularly its oncology treatments. That's only slightly higher than the $63.1 billion to $64.3 billion guidance the company provided in April. Merck reported $16.11 billion in revenue for the quarter, up 7% from the same period a year ago. Some analysts expect that worldwide sales of Winrevair could reach $5 billion by 2030.

Persons: Keytruda, Merck Organizations: Merck, Harpoon Therapeutics, LSEG, Prometheus Biosciences Locations: Rahway , New Jersey, U.S

☆ Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
▼ + stars: | 2024-04-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Merck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as it posted strong sales of its blockbuster cancer drug Keytruda and vaccine products. The pharmaceutical giant also raised and narrowed its full-year revenue and adjusted earnings forecasts. Merck now expects 2024 sales to come in between $63.1 billion and $64.3 billion, up from previous guidance of $62.7 to $64.2 billion. That outlook includes a one-time charge of roughly 26 cents per share related to Merck's acquisition of Harpoon Therapeutics in January. Merck raked in $15.78 billion in revenue for the quarter, up 9% from the same period a year ago.

Persons: Merck Organizations: Merck, Harpoon Therapeutics, LSEG Locations: Rahway , New Jersey, U.S

With interest rate uncertainty on the rise across the market, it may be time to buy stocks with a demonstrated history of low volatility. The Cboe Volatility Index — a yardstick of expected market volatility — briefly rose above 21 on Friday, its highest level since last October. The insurance stock currently has a 5-year beta of 0.54 relative to the S & P 500, and a price volatility score of 6.28. With a 5-year beta of 0.78 versus the S & P 500 and a 5-year price volatility score of 6.50, medical equipment maker Boston Scientific also turned up on the screen. Compared to the S & P 500, Merck's 5-year beta comes in at 0.39, while its 5-year price volatility scores a 6.06.

Persons: Joanne Wuensch Organizations: CNBC Pro, Boston Scientific, Citigroup, Boston, Pharmaceutical, Merck, Food, NextEra Energy Locations: UnitedHealth

☆ Merck CEO Robert Davis discusses FDA approval of its pulmonary arterial hypertension drug
▼ + stars: | 2024-03-27 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Merck CEO Robert Davis discusses FDA approval of its pulmonary arterial hypertension drug'Mad Money' host Jim Cramer speaks with Robert Davis, chairman and CEO of Merck, after the FDA approved the pharmaceutical company's pulmonary arterial hypertension drug, Winrevair.

Persons: Robert Davis, Jim Cramer Organizations: Merck, FDA

☆ Stocks making the biggest moves premarket: Robinhood, GameStop, Merck and more
▼ + stars: | 2024-03-27 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Robinhood — Shares of the brokerage firm jumped more than 6% after unveiling its Robinhood Gold Card, a credit card where cash back can be deposited into a brokerage account. Concentrix — Shares slipped nearly 4% on the back of disappointing fiscal second-quarter earnings guidance. The customer experience technology company also reiterated its full-year outlook for 2024. In the prior session , the stock popped more than 15% on promising trial results for a weight loss pill. Trump Media & Technology Group — Shares of former President Donald Trump's social media company climbed nearly 14% after making its debut as a publicly traded company a day earlier.

Persons: Krispy, McDonald's, Morgan Stanley, Donald Trump's, — CNBC's Michelle Fox, Sarah Min, Jesse Pound Organizations: GameStop, Moderna, Blackstone Life Sciences, Viking Therapeutics, Deutsche Bank, Trump Media & Technology, Merck, Food and Drug Administration, FactSet

☆ FDA approves Merck's drug for rare, deadly lung condition
▼ + stars: | 2024-03-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the drugmaker and for patients suffering from the rare disease. The condition refers to when the small blood vessels in the lungs narrow. He noted that the drug will be a "paradigm shift" for patients living with PAH. That includes reducing the risk of death or worsening of the condition by 84% compared to an existing drug alone. Those trials include late-stage studies on patients with more advanced PAH disease, and those who are within the first year after diagnosis.

Persons: Chris Schott, Eliav Barr, PAH, Barr, Merck Organizations: Merck, Drug Administration, JPMorgan, CNBC, Acceleron Pharma Locations: Rahway , New Jersey, U.S, Winrevair

☆ FDA approves new drug that may help stop and even reverse a rare, fatal condition that doctors call a ‘ticking time bomb’
▼ + stars: | 2024-03-26 | by ( Brenda Goodman | ) edition.cnn.com time to read: +15 min

These proteins cause the walls of a person’s blood vessels to keep growing and thicken over time. As the blood vessels narrow, the heart is forced to work harder to pump blood to the lungs. Treatment with a combination of drugs that dilate, or relax, blood vessels can improve this outlook, but they are not a cure. Both groups were also taking the standard medications for the condition, which help relax blood vessels to improve blood flow. But Galiatsatos said that as promising as the drug looks, there are still many unknowns, including whether the drug will benefit all PAH patients equally.

Persons: Katrina Barry, Barry, “, ”, Winrevair, Merck Winrevair, Vallerie McLaughlin, Panagis, Galiatsatos, isn’t, ” Barry, I’m, fanny, She’s, sotatercept, PAH, Sotatercept, “ There’s, Kristin Highland, Highland, ” Merck, Merck, Dr, Sanjay Gupta, Aaron Waxman, Barry’s, he’s, they’ve, Johnson –, Waxman, “ I’ve, “ It’s, who’ve Organizations: CNN, American Lung Association, US Food and Drug Administration, Merck, FDA, University of Michigan, PAH, Johns Hopkins Bayview Medical Center, New England, of Medicine, Cleveland Clinic, Institute, Clinical, CNN Health, Brigham, Women’s Hospital, Johnson Locations: PAH, American, Greece, Boston

Search resuls for: "Winrevair"

9 mentions found